Fulcrum Asset Management LLP Buys New Holdings in Gilead Sciences, Inc. $GILD

Fulcrum Asset Management LLP purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 8,571 shares of the biopharmaceutical company’s stock, valued at approximately $1,297,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in Gilead Sciences during the 2nd quarter valued at approximately $15,393,785,000. State Street Corp raised its position in shares of Gilead Sciences by 2.3% during the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after buying an additional 1,357,967 shares during the last quarter. Amundi lifted its holdings in shares of Gilead Sciences by 10.7% in the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after buying an additional 1,018,976 shares in the last quarter. Legal & General Group Plc purchased a new position in shares of Gilead Sciences in the second quarter worth $1,316,606,000. Finally, Deutsche Bank AG purchased a new position in shares of Gilead Sciences in the second quarter worth $918,387,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Price Performance

GILD stock opened at $169.73 on Thursday. Gilead Sciences, Inc. has a 52 week low of $116.88 and a 52 week high of $176.58. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. The company has a fifty day simple moving average of $154.40 and a two-hundred day simple moving average of $141.51. The firm has a market capitalization of $210.52 billion, a P/E ratio of -53.71 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The business had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. During the same period last year, the company posted $2.47 EPS. The business’s revenue was up 6.8% on a year-over-year basis. Analysts anticipate that Gilead Sciences, Inc. will post -0.98 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. Gilead Sciences’s dividend payout ratio (DPR) is presently -103.80%.

Insider Buying and Selling

In other news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the transaction, the director owned 10,066 shares in the company, valued at approximately $1,459,771.32. The trade was a 33.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 102,619 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $175.16, for a total value of $17,974,744.04. Following the transaction, the chief executive officer directly owned 551,683 shares in the company, valued at approximately $96,632,794.28. This represents a 15.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 242,709 shares of company stock valued at $39,503,427 in the last quarter. 0.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Zacks Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $165.00 to $190.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Barclays decreased their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 29th. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $170.00 to $190.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Finally, Jefferies Financial Group set a $196.00 price objective on shares of Gilead Sciences in a report on Wednesday, November 4th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $170.15.

Top Gilead Sciences Stories

Investors following GILD have been watching these stories:

• Positive Sentiment: Gilead reported PURPOSE 5 results showing twice-yearly injectable lenacapavir outperformed daily oral HIV prevention on persistence, with no HIV infections in the injectable group. The findings could strengthen the long-term opportunity for its HIV prevention franchise. Gilead Sciences Posts PURPOSE 5 Win As HIV Shot Beats Daily Pills
• Neutral Sentiment: Valuation views are mixed after GILD’s substantial multi-year advance: one analysis sees the shares as undervalued based on cash-flow potential, while another considers them fully valued after the rally. This may make further gains more dependent on continued execution. Gilead Stock Still Looks Undervalued On Its 205% Run Gilead Looks Fully Valued
• Neutral Sentiment: Gilead partner Xilio expects to provide Gilead with an option data package for efarindodekin alfa in the first half of 2027. This is a potential pipeline catalyst, but remains several months away and is dependent on future data. Xilio Therapeutics Pipeline Update

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.